Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (AMGN) is a global biotechnology leader pioneering innovative therapies for serious illnesses. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's latest developments, regulatory milestones, and strategic initiatives.
Track critical updates across Amgen's core therapeutic areas including oncology treatments, inflammatory disease therapies, and rare disease solutions. Our curated feed includes earnings reports, clinical trial data, partnership announcements, and manufacturing updates - all sourced directly from official channels.
Key resources include timely coverage of FDA decisions, research breakthroughs in biologics and biosimilars, and analysis of market-moving events. Bookmark this page for structured access to Amgen's evolving pipeline and business strategies without promotional bias.
Amgen (NASDAQ:AMGN) has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. Kave Niksefat, senior vice president of Global Marketing and Access, will represent the company at the event scheduled for Wednesday, May 21, 2025, at 9:00 a.m. ET.
The presentation will be accessible via webcast to investors, media, and the general public through Amgen's website (www.amgen.com) under the Investors section. The webcast recording will remain available for replay for a minimum of 90 days following the event.
Amgen (NASDAQ:AMGN) has announced its participation in the upcoming Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2025, at 9:20 a.m. PT. The company will be represented by Peter Griffith, executive vice president and CFO, and Jay Bradner, executive vice president of R&D and chief scientific officer.
The presentation will be accessible through a live webcast on Amgen's website (www.amgen.com) under the Investors section. The webcast recording will remain available for replay for at least 90 days following the event.
Amgen (NASDAQ: AMGN) has scheduled its first quarter 2025 financial results announcement for Thursday, May 1, 2025, after market close. The company will host a conference call with the investment community at 4:30 p.m. ET.
Key highlights:
- Leadership Participation: Robert A. Bradway, chairman and chief executive officer, along with other senior management team members will lead the discussion
- Public Access: The event will be accessible to news media, investors, and the general public
- Webcast Details: Live audio will be streamed on www.amgen.com under the Investors section
- Replay Availability: The webcast recording will remain accessible for at least 90 days after the event
Interested parties can find additional information about presentation times and webcast links on Amgen's Investor Relations Events Calendar on their website.
Amgen (NASDAQ: AMGN) has announced a $900 million expansion of its Ohio manufacturing facility, which will create 350 new jobs, bringing the total employment to 750 positions and total investment in Central Ohio to over $1.4 billion.
The expansion builds upon Amgen's initial entry into Ohio in June 2021, when it established a state-of-the-art biomanufacturing facility that created 400 jobs. This investment is part of Amgen's broader U.S. manufacturing strategy, which includes nearly $5 billion in direct capital expenditures since 2017, generating approximately $12 billion in additional downstream output to the U.S. economy.
The Ohio expansion enhances Amgen's global biomanufacturing network and follows the company's recent announcement of a $1 billion investment for a second manufacturing plant in Holly Springs, NC.
Amgen (NASDAQ:AMGN) announced significant breakthrough in their Phase 3 DeLLphi-304 clinical trial for IMDELLTRA® (tarlatamab-dlle), a treatment for small cell lung cancer (SCLC). The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in overall survival (OS) compared to standard-of-care chemotherapy.
The global Phase 3 trial focused on patients who progressed on or after a single line of platinum-based chemotherapy. The study compared IMDELLTRA against local standard-of-care treatments including topotecan, lurbinectedin, and amrubicin depending on the region. The safety profile remained consistent with previously known data.
Dr. Jay Bradner, Executive VP of Research and Development at Amgen, emphasized the overwhelming clinical benefit for patients with this aggressive malignancy. Detailed trial results are scheduled for presentation at an upcoming medical congress.
Amgen (NASDAQ:AMGN) has received FDA approval for UPLIZNA as the first and only treatment for adults with Immunoglobulin G4-related disease (IgG4-RD), a chronic immune-mediated inflammatory condition affecting multiple organs. The FDA granted Breakthrough Therapy Designation for this indication.
The approval is supported by the MITIGATE trial, which demonstrated an 87% reduction in flare risk versus placebo. UPLIZNA, a CD19+ B-Cell targeted therapy, showed effectiveness in achieving corticosteroid-free, flare-free complete remission.
This marks UPLIZNA's second FDA-approved indication, following its June 2020 approval for NMOSD treatment. Amgen is also pursuing regulatory approval for generalized myasthenia gravis (gMG), with submission planned for H1 2025.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
